Navigation Links
U.S. Navy Submits Protocol for Field Trauma Trial of Hemopure(R)
Date:6/18/2008

uma trial. In carrying out that agreement, the Navy designed and submitted to the FDA a proposed phase 2/3 trial entitled "Restore Effective Survival in Shock" (RESUS). That trial would have been conducted prehospital in civilian trauma patients. The trial was placed on clinical hold by the FDA and continues to be on hold following changes intended to address FDA comments. The newly filed protocol, by incorporating informed consent, is intended to remove requirements attendant to waiver of informed consent. To date, Congress has appropriated a total of $24.2 million for the development of Hemopure.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. The Company is developing Hemopure for other indications and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 200,000 units of Oxyglobin since its launch.

Statements in this release that are not strictly historical are forward- looking statements, including any statements implying that any clinical trial will be initiated and/or carried out to completion or that study results will be as desired, and any statements that might imply that Hemopure may receive marketing approval in any jurisdictions other than South Africa or for a trauma indication anywhere. Actual results and their timing may differ materially from those projected in these for
'/>"/>

SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
3. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
4. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
5. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
6. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
7. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
8. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
9. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
10. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
11. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , September 2, 2014 ... including patients, quality of life and treatment satisfaction [ ... 2 ]   ... Congress 2014, 02 September 2014, Barcelona, Spain ... of the PREvention oF thromboembolic events-European Registry in Atrial ...
(Date:9/2/2014)... YORK , September 2, 2014 ... WellPoint Inc. (NYSE: WLP ), Tekmira Pharmaceuticals ... ZTS ), Sanofi SA (NYSE: ... members receive these notes ahead of publication. To reserve ... . , ,-- ,WellPoint Inc. Research Reports ,WellPoint Inc. ...
(Date:9/2/2014)... HOUSTON , Sept. 2, 2014  Cyberonics, ... results from the ANTHEM-HF clinical study.  Results of ... specialist during a major European cardiology congress and ... Failure show Autonomic Regulation Therapy (ART) in ... and impaired heart function is safe, improves the ...
Breaking Medicine Technology:One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 2One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 3One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 4One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 5One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 6One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 7One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 8Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 4Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 5Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 6ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 2ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 3ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 4ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 5
... 20 Thomson Reuters, a global provider ... the newest version of its award-winning Clinical ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090507/NY12658LOGO) (Logo: ... hospital-based clinicians to access complete patient clinical ...
... VPHM ) third quarter financial results for 2010 ... before the open of the U.S. financial markets. ... webcast at 9:00 a.m. Eastern Time on the same day. ... third quarter financial results and other business. ...
Cached Medicine Technology:Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator 2Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator 3ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010 2
(Date:9/2/2014)... September 02, 2014 On August 30, ... website titled “Why You Should Wash Your Face ... of the global population breathes air considered polluted by ... pollution lodge in the skin’s pores destroying its natural ... to free radicals that may cause cell damage, redness, ...
(Date:9/2/2014)... lay the groundwork for their own spread throughout the ... out tumor-welcoming signals, according to a new report by ... issue of Nature Communications , the researchers describe ... so-called signaling molecules released by breast cancer cells. These ... and lymph nodes to produce proteins called CCL5 and ...
(Date:9/2/2014)... Doheny HealthDay Reporter TUESDAY, ... is a driving force behind the rising rates of type ... at data from five national surveys spanning from 1976 through ... time could be explained by factors such as changing distribution ... investigators found that the prevalence of diabetes in men rose ...
(Date:9/2/2014)... (HealthDay News) -- A leading group of oncologists has ... form of advanced breast cancer. HER2-negative breast ... target the HER2 protein, the American Society of Clinical ... Almost 80 percent of women with advanced breast ... releasing this guideline, our aim is to improve both ...
(Date:9/2/2014)... ALEXANDRIA, VAThe latest research on sleep apnea, tonsillectomies, ... otolaryngic topics will be presented in Orlando, FL, ... OTO EXPO℠ of the American Academy of OtolaryngologyHead ... meeting of ear, nose, throat, head and neck ... research to be presented were released today, and ...
Breaking Medicine News(10 mins):Health News:Simon Ourian, Kim Kardashian’s Doctor: Air Pollution May Be Aging Your Skin 2Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3Health News:New Guidelines for Treating Form of Advanced Breast Cancer 2
... and the University of Florida Proton Therapy Institute have formed ... The announcement follows the approval of the first clinical study ... cancers in children younger than 3 years old. ... to receive proton therapy at the UF Proton Therapy Institute ...
... respiratory disease, often leading to disability or an increased ... Studies led by Deborah Young-Corbett, a faculty member ... specific types of sanding tools are highly effective in ... the industry,s usage of the available technology remains very ...
... -- The lives of almost 4 million women, newborns, ... year if well-established, affordable health care interventions reached 90 ... the national science academies of seven African countries. ... save lives, says the report, which calls on scientists, ...
... ... Texas , is sponsoring a new video contest inviting participants to describe why they are ... worth up to $15,000, and submitted videos will be shown on Austin Dental Spa’s website ... ...
... ... Self-service Kiosks and Pricing Transparency Patient Estimations. , ... Denver, CO (PRWEB) November 9, 2009 ... a partnership that provides patients more control when interacting with providers by understanding ...
... ... Ask4UFE to launch a podcast series that helps women suffering in silence understand their ... ... but they are life altering, says supermodel Beverly Johnson, during a new 3-part ...
Cached Medicine News:Health News:St. Jude and UF Proton Therapy Institute to begin proton therapy clinical trial 2Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 2Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 3Health News:Using science to save lives of mothers and children in Africa 2Health News:Using science to save lives of mothers and children in Africa 3Health News:Using science to save lives of mothers and children in Africa 4Health News:Austin Cosmetic Dentist Offers $15,000 Worth of Dental Work in Most Interesting Patient in the World Video Contest 2Health News:Austin Cosmetic Dentist Offers $15,000 Worth of Dental Work in Most Interesting Patient in the World Video Contest 3Health News:FHS Corp. Announces Partnership with Vecna Technologies 2Health News:New Series of Podcasts Highlight Supermodel's "Life-altering" Experience to Raise Awareness of Fibroid Treatment Options 2
Ergotec Vetriretinal Instrument System. Reverse action jaws. 0.4 mm cupped tips....
Designed to securely hold scleral plugs during insertion and removal. The cross action handle is designed to reduce hand fatigue while grasping plug....
For use with the Landers Vitrectomy Lens set (MVS 1079A). Shafts angled 45 degrees with curved grooved blades for holding the Landers vitrectomy lenses. Polished finish....
Ergotec Vetriretinal Instrument System. Ultra-fine angled tips (4 mm) with 20 gauge shaft. 25 mm in length. Overall length from rear rotation knob to tip....
Medicine Products: